PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.95%
Reduced diluted shares while XRF.AX is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-2963.60%
Negative OCF growth while XRF.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-174.00%
Negative FCF growth while XRF.AX is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-92.95%
Negative 10Y revenue/share CAGR while XRF.AX stands at 30.52%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-67.73%
Negative 5Y CAGR while XRF.AX stands at 30.52%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-68.10%
Negative 3Y CAGR while XRF.AX stands at 8.66%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-101.31%
Negative 10Y OCF/share CAGR while XRF.AX stands at 4540.47%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
94.53%
Below 50% of XRF.AX's 4540.47%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-112.81%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-111.55%
Negative 10Y net income/share CAGR while XRF.AX is at 875.24%. Joel Greenblatt sees a major red flag in long-term profit erosion.
81.82%
Below 50% of XRF.AX's 875.24%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
19.58%
3Y net income/share CAGR 50-75% of XRF.AX's 32.24%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.88%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-1.24%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-9.00%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.